

NEWS 43 Jun 06 PASCAL enhanced with additional data

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:36:46 ON 16 JUN 2003

=> file medline, caplus, uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 15:37:03 ON 16 JUN 2003

FILE 'CAPLUS' ENTERED AT 15:37:03 ON 16 JUN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:37:03 ON 16 JUN 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s IL-4 (5a) (receptor#)

L1 2817 IL-4 (5A) (RECEPTOR#)

=> s l1 (p) (powder#)

L2 8 L1 (P) (POWDER#)

=> d l2 1-8 bib ab

L2 ANSWER 1 OF 8 USPATFULL

AN 2003:127633 USPATFULL

TI Immunostimulatory nucleic acids for the treatment of asthma and allergy

IN Bratzler, Robert L., Concord, MA, UNITED STATES

Petersen, Deanna M., Newton, MA, UNITED STATES

Fouron, Yves, Marlboro, MA, UNITED STATES

PI US 2003087848 A1 20030508

AI US 2001-776479 A1 20010202 (9)

PRAI US 2000-179991P 20000203 (60)

DT Utility

FS APPLICATION

LREP Helen C. Lockhart, c/o Wolf Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210

CLMN Number of Claims: 36

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8826

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.

L2 ANSWER 2 OF 8 USPATFULL

AN 2003:106233 USPATFULL

TI Compositions and methods for the therapy and diagnosis of pancreatic cancer

IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2003073144 A1 20030417

AI US 2002-60036 A1 20020130 (10)

PRAI US 2001-333626P 20011127 (60)

US 2001-305484P 20010712 (60)

US 2001-265305P 20010130 (60)

US 2001-267568P 20010209 (60)

US 2001-313999P 20010820 (60)

US 2001-291631P 20010516 (60)

US 2001-287112P 20010428 (60)

US 2001-278651P 20010321 (60)

US 2001-265682P 20010131 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

L2 ANSWER 3 OF 8 USPATFULL

AN 2002:272801 USPATFULL

TI Compositions and methods for the therapy and diagnosis of colon cancer

IN Stolk, John A., Bothell, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Chenault, Ruth A., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2002150922 A1 20021017

AI US 2001-998598 A1 20011116 (9)

PRAI US 2001-304037P 20010710 (60)

US 2001-279670P 20010328 (60)

US 2001-267011P 20010206 (60)

US 2000-252222P 20001120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly colon cancer, are disclosed. Illustrative compositions
comprise one or more colon tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly colon cancer.

L2 ANSWER 4 OF 8 USPATFULL

AN 2002:243051 USPATFULL

TI Compositions and methods for the therapy and diagnosis of ovarian cancer

IN Algate, Paul A., Issaquah, WA, UNITED STATES

Jones, Robert, Seattle, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2002132237 A1 20020919

AI US 2001-867701 A1 20010529 (9)

PRAI US 2000-207484P 20000526 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 25718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly ovarian cancer, are disclosed. Illustrative compositions
comprise one or more ovarian tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly ovarian cancer.

L2 ANSWER 5 OF 8 USPATFULL

AN 2002:242791 USPATFULL

TI Compositions and methods for the therapy and diagnosis of colon cancer

IN King, Gordon E., Shoreline, WA, UNITED STATES

Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

Xu, Jiangchun, Bellevue, WA, UNITED STATES

Serist, Heather, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

PI US 2002131971 A1 20020919

AI US 2001-33528 A1 20011226 (10)

RLI Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001,
PENDING

PRAI US 2001-302051P 20010629 (60)

US 2001-279763P 20010328 (60)

US 2000-223283P 20000803 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8083

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

L2 ANSWER 6 OF 8 USPATFULL

AN 2002:227675 USPATFULL

TI Solid peptide preparations for inhalation and their preparation

IN Lizio, Rosario, Buttelborn, GERMANY, FEDERAL REPUBLIC OF

Damm, Michael, Rodermark, GERMANY, FEDERAL REPUBLIC OF

Sarlikiotis, Werner, Peania, GREECE

Wolf-Heuss, Elisabeth, Mosbach, GERMANY, FEDERAL REPUBLIC OF

PI US 2002122826 A1 20020905

AI US 2001-944060 A1 20010831 (9)

PRAI DE 2000-10043509 20000901

DT Utility

FS APPLICATION

LREP Goodwin Procter L.L.P., 599 Lexington Avenue, 40th floor, New York, NY, 10022

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 764

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to solid pharmaceutical preparations, in particular for inhalatory administration in mammals, their preparation and their use such as, for example, in powder inhalers.

L2 ANSWER 7 OF 8 USPATFULL

AN 2002:194562 USPATFULL

TI Compositions and methods for specifically targeting tumors

IN Debinski, Waldemar, Hummelstown, PA, United States

Puri, Raj K., North Potomac, MD, United States

PA Penn State University, United States (U.S. corporation)

PI US 6428788 B1 20020806

AI US 1996-706207 19960830 (8)

RLI Continuation-in-part of Ser. No. US 1995-404685, filed on 15 Mar 1995, now patented, Pat. No. US 5614191

DT Utility

FS GRANTED

EXNAM Primary Examiner: Eyler, Yvonne; Assistant Examiner: Andres, Janet L.

LREP Akerman Senterfitt, Kim, Stanley A.

CLMN Number of Claims: 53

ECL Exemplary Claim: 1,43

DRWN 11 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 3421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell. The method involves providing a chimeric molecule comprising an effector molecule attached to a targeting molecule that specifically binds an IL-13 receptor and contacting a tumor cell with the chimeric molecule in the presence of an interleukin-4 receptor (IL-4R) blocker.

L2 ANSWER 8 OF 8 USPATFULL

AN 97:51851 USPATFULL

TI Cell-free receptor binding assays, the production and use thereof
 IN Lauffer, Leander, Marburg, Germany, Federal Republic of
 Zettlmeissl, Gerd, Wetter, Germany, Federal Republic of
 Oquendo, Patricia, Marburg, Germany, Federal Republic of
 PA Behringwerke Aktiengesellschaft, Marburg, Germany, Federal Republic of
 (non-U.S. corporation)
 PI US 5639597 19970617
 AI US 1994-243010 19940513 (8)
 RLI Continuation of Ser. No. US 1993-110798, filed on 23 Aug 1993, now
 abandoned which is a continuation of Ser. No. US 1991-798564, filed on
 26 Nov 1991, now abandoned
 PRAI DE 1990-4037837 19901128
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Mosher, Mary E.; Assistant Examiner: Wortman, Donna C.
 LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
 CLMN Number of Claims: 26
 ECL Exemplary Claim: 1
 DRWN 17 Drawing Figure(s); 15 Drawing Page(s)
 LN.CNT 584

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to cell-free receptor binding assays which permit
 the binding behavior of receptor proteins in the cell membrane toward
 natural or artificial ligands to be investigated. This entails the
 particular receptor being linked to a suitable carrier molecule,
 preferably the heavy chain of an immunoglobulin, and being bound via the
 carrier, with retention of its biological property, to a suitable solid
 phase.

=> d 12 1-8 kwic

L2 ANSWER 1 OF 8 USPATFULL
 DETD . . . Aerobid (flunisolide) Steroid
 IVAX Ventolin (salbutamol)
 Bronchodilator/beta-2 agonist
 Becotide (beclomethasone Easi-Breathe) Steroid
 Serevent (salmeterol)
 Bronchodilator/beta-2 agonist Steroid
 Flixotide (fluticasone)
 Budesonide Dry Powder Inhaler
 Steroid
 Salbutamol Dry Powder Inhaler
 Bronchodilator/beta-2 agonist
 Alza Volmax (salbutamol)
 Bronchodilator/beta-2 agonist
 Altana Euphyllin (theophylline)
 Xanthanine
 Ciclesonide
 Arachidonic acid antagonist
 BY 217 PDE 4
 inhibitor
 BY. . . Thromboxane A2 antagonist
 BAY 16-9996 (once monthly dosing) IL4
 mutein
 BAY 19-8004 PDE-4
 inhibitor
 SR Pharma SRL 172
 Immunomodulation
 Immunex Nuvance Soluble
 IL-4 receptor (immunomo
 dulator)
 Biogen Anti-VLA-4

Immunosuppressant		
Vanguard	VML 530	Inhibitor
	of 5-lipox activation	
		protein
Recordati	Respix (zafirlukast)	
	Leukotriene antagonist	
Genentech	Anti-IgE MAb	
	Down-regulator of IgE	
Warner	CI-1018.	

L2 ANSWER 2 OF 8 USPATFULL
SUMM [2043] SEQ ID NO:2003 is the determined cDNA sequence of clone 61496359

L2 ANSWER 3 OF 8 USPATFULL
SUMM [2044] SEQ ID NO:1997 is the determined cDNA sequence for clone 62227174
R0394:B12

L2 ANSWER 4 OF 8 USPATFULL
SUMM [2043] SEQ ID NO: 2004 represents the cDNA sequence for clone AA165409.

L2 ANSWER 5 OF 8 USPATFULL
SUMM [2042] Alternatively, amplification techniques, such as those described above, can be useful for obtaining a full length coding sequence from a partial cDNA sequence. One such amplification technique is inverse PCR (see Triglia et al., Nucl. Acids Res. 16:8186, 1988), which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a linker sequence and a primer specific to a known region. The amplified sequences are typically subjected to a second round of amplification with the same linker primer and a second primer specific to the known region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from. . .

L2 ANSWER 6 OF 8 USPATFULL
SUMM [0007] In addition, it is possible to employ for the preparation of micronized powders for inhalatory or other purposes or powder formulations for inhalation, for example: M3 antagonists such as, for example, LAS34273 (also known under the name LAS W 330, . . . (dual beta-2 and dopamine D2 agonist COPD, Astra Zeneca), IPL 576,092 (Aventis), RPR 106-541 (steroid, Aventis), RP73401 (PDE-IV, Aventis), IL-4r (IL-4 receptor, Immunex/Aventis), BAY 16 9996 (IL-4 receptor antagonist, Bayer), ciclesonide (steroid, Byk-Gulden), romiflulast (PDE-IV inhibitor, Byk-Gulden), D-4418 (PDE-4, Darwin), EpiGenRx (adenosine A1, antisense, EpiGenesis), FR173657 (bradykinin antagonist, . . .

L2 ANSWER 7 OF 8 USPATFULL
DETD The chimeric molecules and IL-4 receptor blockers of this invention are useful for parenteral, topical, oral, or local administration, such as by aerosol or transdermally, for. . . be administered in a variety of unit dosage forms depending upon the method of administration; for example oral administration include powder, tablets, pills, capsules and lozenges. It is recognized that the fusion proteins and IL-4R blockers and pharmaceutical compositions of this. . .

L2 ANSWER 8 OF 8 USPATFULL

DETD DE P 4020 607.6 discloses the protein IL-4RFc. It is composed of the extracellular portion of the human **receptor** for IL-4 which is fused to the Fc part of the heavy chain of a human IgG1 molecule. ELISA plates (Nunc, type. . . five times with PBS containing 0.05% Tween 20 and then incubated with 275 .mu.l of PBS containing 5% skim milk **powder** at room temperature for 60 min and then washed as above. Then a "checkerboard titration" was initially carried out in. . .